Controversy persists as to whether systemic chemotherapy is beneficial treatment for stage IV non-small cell lung cancer (NSCLC). Combination chemotherapy used to treat patients with metastatic NSCLC is not associated with long-term survival. Nevertheless, a survival benefit has been demonstrated in ...
Metastatic non-small cell lung cancer (NSCLC) is a highly fatal and immunogenic malignancy. Although the immune system is known to recognize these tumor cells, one mechanism by which NSCLC can evade the immune system is via overexpression of programmed cell death ligand 1 (PD-L1). Recent clini...
Aim: To estimate the incidence, prevalence and treated prevalence by line of therapy (LOT) for non-small-cell lung cancer (NSCLC) patients without driver mutations from 2021 to 2026. Materials & methods: Country-specific registry data for Western Europe were used to project incidence and prevalen...
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist. 2010; 15:1344-51.Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). MH Cohen,JR Johnson,S Chattopadhyay,S Tang,R Justice,R...
GUIDELINE QUESTION: In patients with metastatic, stage IV non-small-cell lung cancer (NSCLC) does chemotherapy improve survival and quality of life? OBJECTIVE: To make recommendations about the role of chemotherapy in the treatment of metastatic (stage IV) NSCLC. OUTCOMES: Survival and quality of...
Non-Small Cell Lung Cancer Stage \\{IV\\} Long-Term Survival With Isolated Spleen Metastasis N. Younes, "Non-small cell lung cancer stage IV long-term survival with isolated spleen metastasis," e Annals of oracic Surgery, vol. 95, no. 4,... Rodrigo A.S. Sardenberg and Clovis Pinto...
IO, immunotherapy; NSCLC, non-small-cell lung cancer; PD-(L)1, programmed cell death protein 1/programmed death-ligand 1. Proposed criteria for acquired resistance in immunotherapy in NSCLC Type of treatment In order to define who has developed AR to PD-(L)1 blockade, strict and specific ...
Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages? Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages? Ther Adv Med Oncol ... Desly...
Palliative care models are lacking in the comprehensive care of patients with lung cancer. We describe the quality of life in patients with non-small-cell lung cancer and the development of an interdisciplinary palliative care intervention. A total of 114 patients reported on function, cognition, ...
The FDA granted approval to capmatinib (Tabrecta) for adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.1 ...